NCG|Strain NO.T001475

Knockout (KO)

  • Product Type:
  • Quantity: - +
  • Sex:
  • Age:
  • Genotype:
Strain Name: NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt
Strain Number: T001475
Official Symbol: Prkdc,Il2rg
Strain Strategy: T001475.NCG strain info.pdf
Official Full Name: protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As: AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number: 1909016186
MGI Number: 10477996551
Research Areas: Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background: [N000235] NOD/ShiLtJGpt
Modification Type: Knockout (KO)
Inventory Status: Live,Cryopreserved
Sale Status: IF (Available for Distribution)
Health Status: Specific pathogen free (SPF)
Health Report: Please log in to view
Publications: 1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN38. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES19. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling10. Creatine promotes cancer metastasis through activation of Smad2/311. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK134. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance37. Impaired histone inheritance promotes tumor progression38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES139. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity58. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models59. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT60. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer61. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD5162. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma63. Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway64. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application65. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma66. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma67. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming68. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity69. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects70. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation71. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting72. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts73. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)74. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma75. Endoplasmic reticulum aminopeptidase 2 regulates CD4(+) T cells pyroptosis in rheumatoid arthritis76. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA977. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement78. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma79. RORalpha is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis80. High-fat diet promotes prostate cancer metastasis via RPS2781. CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma82. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments83. RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid84. Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody85. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer86. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial87. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology88. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy89. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer90. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/beta-catenin/PD-L1 axis91. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia92. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer93. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion94. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer95. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells